Insider Selling: Adamis Pharmaceuticals Corp (NASDAQ:ADMP) CEO Sells 10,477 Shares of Stock

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) CEO Dennis J. Phd Carlo sold 10,477 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $1.06, for a total transaction of $11,105.62. Following the transaction, the chief executive officer now directly owns 353,930 shares in the company, valued at $375,165.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

ADMP opened at $1.05 on Friday. The company has a market capitalization of $65.13 million, a price-to-earnings ratio of -1.05 and a beta of 1.28. The company has a quick ratio of 0.79, a current ratio of 1.04 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average price of $1.16 and a 200-day moving average price of $1.87. Adamis Pharmaceuticals Corp has a twelve month low of $0.93 and a twelve month high of $4.25.

Adamis Pharmaceuticals (NASDAQ:ADMP) last posted its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.03). The business had revenue of $5.77 million during the quarter, compared to analysts’ expectations of $5.82 million. Adamis Pharmaceuticals had a negative return on equity of 86.04% and a negative net margin of 205.32%. On average, sell-side analysts expect that Adamis Pharmaceuticals Corp will post -0.46 earnings per share for the current fiscal year.

A number of research analysts recently weighed in on ADMP shares. Raymond James set a $4.00 price target on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, May 10th. Zacks Investment Research lowered shares of Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 13th. Dawson James started coverage on shares of Adamis Pharmaceuticals in a research report on Tuesday, July 2nd. They set a “buy” rating on the stock. Maxim Group set a $6.00 price target on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, B. Riley raised shares of Adamis Pharmaceuticals from a “sell” rating to a “neutral” rating in a research report on Tuesday, July 23rd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $3.87.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Leisure Capital Management increased its stake in shares of Adamis Pharmaceuticals by 4.5% in the first quarter. Leisure Capital Management now owns 115,724 shares of the specialty pharmaceutical company’s stock worth $244,000 after purchasing an additional 4,967 shares in the last quarter. National Asset Management Inc. increased its stake in shares of Adamis Pharmaceuticals by 28.9% in the first quarter. National Asset Management Inc. now owns 29,920 shares of the specialty pharmaceutical company’s stock worth $64,000 after purchasing an additional 6,710 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Adamis Pharmaceuticals in the fourth quarter worth about $31,000. BlackRock Inc. increased its stake in shares of Adamis Pharmaceuticals by 1.5% in the second quarter. BlackRock Inc. now owns 962,687 shares of the specialty pharmaceutical company’s stock worth $1,252,000 after purchasing an additional 14,312 shares in the last quarter. Finally, Wedbush Securities Inc. purchased a new position in shares of Adamis Pharmaceuticals in the first quarter worth about $39,000. Hedge funds and other institutional investors own 19.45% of the company’s stock.

Adamis Pharmaceuticals Company Profile

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Featured Story: What is meant by holder of record?

Insider Buying and Selling by Quarter for Adamis Pharmaceuticals (NASDAQ:ADMP)

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.